These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 2170005

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Developmental changes in muscarinic receptor-stimulated phosphoinositide metabolism in rat brain.
    Balduini W, Murphy SD, Costa LG.
    J Pharmacol Exp Ther; 1987 May; 241(2):421-7. PubMed ID: 3033215
    [Abstract] [Full Text] [Related]

  • 4. Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells.
    Kasayama S, Saito H, Kouhara H, Sumitani S, Sato B.
    J Cell Physiol; 1993 Feb; 154(2):254-61. PubMed ID: 7678839
    [Abstract] [Full Text] [Related]

  • 5. Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation.
    Donato NJ, Ince C, Rosenblum MG, Gallick GE.
    J Cell Biochem; 1989 Nov; 41(3):139-57. PubMed ID: 2482293
    [Abstract] [Full Text] [Related]

  • 6. Activation of calcium-dependent kinases and epidermal growth factor receptor regulate muscarinic acetylcholine receptor-mediated MAPK/ERK activation in thyroid epithelial cells.
    Montiel M, Quesada J, Jiménez E.
    Cell Signal; 2007 Oct; 19(10):2138-46. PubMed ID: 17643958
    [Abstract] [Full Text] [Related]

  • 7. Ionic signal transduction in growth factor action.
    De Laat SW, Moolenaar WH, Defize LH, Boonstra J, van der Saag PT.
    Biochem Soc Symp; 1985 Oct; 50():205-20. PubMed ID: 3019351
    [Abstract] [Full Text] [Related]

  • 8. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
    Kalli KR, Bradley SV, Fuchshuber S, Conover CA.
    Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362
    [Abstract] [Full Text] [Related]

  • 9. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity.
    Huang JS, Nishimura J, Huang SS, Deuel TF.
    J Cell Biochem; 1984 Sep; 26(4):205-20. PubMed ID: 6099364
    [Abstract] [Full Text] [Related]

  • 10. Muscarinic stimulation of phosphatidylinositol metabolism in atria.
    Brown SL, Brown JH.
    Mol Pharmacol; 1983 Nov; 24(3):351-6. PubMed ID: 6633501
    [Abstract] [Full Text] [Related]

  • 11. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM, Saigal B, Donato NJ.
    J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
    [Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor alters metabolism of inositol lipids and activity of protein kinase C in mouse embryo palate mesenchyme cells.
    Chepenik KP, Haystead TA.
    J Craniofac Genet Dev Biol; 1989 Nov; 9(3):285-301. PubMed ID: 2613862
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid cells following psoralen/ultraviolet light treatment.
    Mermelstein FH, Abidi TF, Laskin JD.
    Mol Pharmacol; 1989 Dec; 36(6):848-55. PubMed ID: 2557535
    [Abstract] [Full Text] [Related]

  • 14. The protein kinase C inhibitor Go6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] potentiates agonist-induced mitogen-activated protein kinase activation through tyrosine phosphorylation of the epidermal growth factor receptor.
    Shah BH, Olivares-Reyes JA, Catt KJ.
    Mol Pharmacol; 2005 Jan; 67(1):184-94. PubMed ID: 15465928
    [Abstract] [Full Text] [Related]

  • 15. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells.
    Cardinali M, Sartor O, Robbins KC.
    J Clin Invest; 1992 Apr; 89(4):1242-7. PubMed ID: 1556185
    [Abstract] [Full Text] [Related]

  • 16. Butyrate-induced alterations of phosphoinositide metabolism, protein kinase C activity and reduced CD44 variant expression in HT-29 colon cancer cells.
    Kopp R, Fichter M, Assert R, Pfeiffer AF, Classen S.
    Int J Mol Med; 2009 May; 23(5):639-49. PubMed ID: 19360323
    [Abstract] [Full Text] [Related]

  • 17. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression.
    Mills GB, Zhang N, May C, Hill M, Chung A.
    Cancer Res; 1990 May 15; 50(10):3036-42. PubMed ID: 1692253
    [Abstract] [Full Text] [Related]

  • 18. Muscarinic receptor stimulated phosphoinositide turnover in cardiac atrial tissue.
    Quist EE, Satumtira N.
    Biochem Pharmacol; 1987 Feb 15; 36(4):499-505. PubMed ID: 3030327
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines.
    Lokshin A, Peng X, Campbell PG, Barsouk A, Levitt ML.
    Cancer Chemother Pharmacol; 1999 Feb 15; 43(4):341-7. PubMed ID: 10071987
    [Abstract] [Full Text] [Related]

  • 20. The NMR solution structure of human epidermal growth factor (hEGF) at physiological pH and its interactions with suramin.
    Huang HW, Mohan SK, Yu C.
    Biochem Biophys Res Commun; 2010 Nov 26; 402(4):705-10. PubMed ID: 21029725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.